In contrast to neuroendocrine neoplasms, a significant decrease in the overall p16Ink4A expression was observed for the non-neuroendocrine carcinomas, moving from well differentiated to poorly and undifferentiated entities (p <0.05, Anova) (S2 Fig). The gene discussed is CDKN2A; the disease is neuroendocrine carcinoma.